CRI Logo
  • About
    • Impact
    • History
    • Team
    • Careers
    • Blog
    • Media Room
  • What is Immunotherapy?
    • Immunotherapy Basics
    • Treatment Types
    • Cancer Types
    • Side Effects
  • Patient Support
    • Patient Resources
    • Clinical Trials
    • Immunotherapy Stories
    • Connect with ImmunoAdvocates
  • Grants & Research Programs
    • Apply for Grants
    • Clinical Accelerator
    • Data Programs
    • CRI Funded Scientists
  • Get Involved
    • Ways to Give
    • Fundraise
    • Events
    • Partnership
    • Contact
Donate

Immune to Cancer: The CRI Blog

  • Kim Hyung Jun

    CRI Funded Scientist

    Hyung Jun Kim, PhD

    While modern immunotherapies have revolutionized treatment for certain cancers, they remain largely ineffective against solid tumors such…
  • Joe Kern

    CRI Funded Scientist

    Joseph Kern, PhD

    One of the major challenges in cancer biology is understanding how tumors escape detection by the immune…
  • Fubo Ji

    CRI Funded Scientist

    Fubo Ji, PhD

    Immunotherapy has transformed cancer treatment by harnessing the body’s own immune system to destroy tumors. Yet most…
  • Zhouping Hong

    CRI Funded Scientist

    Zhouping Hong, PhD

    The innate immune system serves as the body’s first line of defense against infection and injury, relying…
  • Ron Gejman

    CRI Funded Scientist

    Ron Gejman, MD, PhD

    Organ transplant recipients must take lifelong immunosuppressive drugs to prevent rejection of their transplanted organ. While lifesaving,…
  • Xueyang Dong

    CRI Funded Scientist

    Xueyang Dong, PhD

    The immune system’s T cells play a central role in recognizing and eliminating cancer, yet how they…
  • Maria Cardenas

    CRI Funded Scientist

    Maria Cardenas Conti, PhD

    Immunotherapy has revolutionized cancer treatment, yet many patients still do not achieve lasting benefit. Among the key…
  • Emmanuella Adjei-Sowah

    CRI Funded Scientist

    Emmanuela Adjei-Sowah, PhD

    Clear cell renal cell carcinoma (ccRCC) is one of the most common and deadly forms of kidney…
  • CRI Funded Scientist

    Rachael Safyan, MD

    Pancreatic cancer is one of the most aggressive and deadly cancers, with less than 15% of patients…
Previous Page
1 2 3 4 5 … 29
Next Page
Father and son

Join CRI in Shaping the Future of Immunotherapy

Support the pioneering work of CRI in advancing immunotherapy.

See ways to give

Cancer Research Institute
29 Broadway, Floor 4

New York, NY  10006-3111

Facebook Icon
X icon
YouTube icon
LinkedIn icon
Instagram icon
Threads icon
  • About
    • Impact
    • History
    • Team
    • Careers
    • Blog
    • Media Room
  • What is Immunotherapy?
    • Immunotherapy Basics
    • Treatment Type
    • Cancer Type
    • Side Effects
  • Patient Support
    • Patient Resources
    • Clinical Trials
    • Immunotherapy Stories
    • Connect with ImmunoAdvocates
  • Grants & Research Programs
    • Apply for Grants
    • Clinical Accelerator
    • Data Programs
    • CRI Funded Scientists
  • Get Involved
    • Donate
    • Ways to Give
    • Fundraise
    • Events
    • Partnership
    • Contact

Uniting for a World Immune to Cancer

  • Accessibility Statement
  • Privacy Policy
  • Terms & Conditions
  • Site Map

*Immunotherapy results may vary from patient to patient.

©2026, Cancer Research Institute